The lawsuits allege the company made false and/or misleading statement and/or failed to disclose information that was pertinent to investors.
The firm is in the midst of evaluating its strategic options and has hired Raymond James to assist in the process, which could include the sale of the firm, it said.
The companies will join their respective technologies into a precision oncology testing and analysis offering.
Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.
Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.
The program enables NJ-based tech firms to sell net operating losses and R&D tax credits for at least 80 percent of the value of the tax benefits.
The test, which also is FDA-approved, can be used to identify best responders to three non-small cell lung cancer treatment regimens.
The company plans to offer 3.5 million units, comprising one share of common stock and one warrant to buy an additional share, at $2 per unit.
The partners will collaborate on educational and collaborative oncology clinical research activities in India to drive use of genomic technologies.
The revenue increase was primarily driven by increased revenue in the company's biopharma services, clinical services, and discovery services divisions.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.